Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation

• Status: Terminated
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy and safety of angiotensin converting enzyme inhibition (ACE-I) therapy for the treatment of mitral regurgitation (MR).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Utah
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI); Pediatric Heart Network
• Treatments: Enalapril; Enalaprilat

Criteria

Inclusion Criteria:

• Children less than 18 years of age and at least 6 months post AVSD repair or reoperation

• At least moderate MR

• Asymptomatic or minimally symptomatic, defined by Ross Heart Failure Class I or II

• Atrioventricular synchrony (paced or intrinsic)

Exclusion Criteria:

• Tetrology of Fallot, total or partial anomalous venous connection

• More than trivial MS or outflow obstruction

• Other sources of LV volume overload

• Hypertrophic obstructive cardiomyopathy

• Significant residual coarctation